Abstract
RNA interference (RNAi) is a powerful endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. The ability to block the expression of any disease-causing or disease-related protein emphasizes the huge therapeutic potential of this technology. In a clinical setting, however, the use of RNAi-based therapeutics is limited by their short serum half lives and poor uptake into cells. In this review, we provide an overview of recent patents in the field of short interfering RNA (siRNA) delivery and discuss recent progress in the development of efficient siRNA delivery vehicles enhancing the pharmacokinetic properties of RNAi-based therapeutics and promoting cellular uptake.
Keywords: RNA interference, specific knock-down, non-targeted delivery, targeted delivery, cell-specific ligands
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Volume: 4 Issue: 1
Author(s): Ulrich Wullner, Inga Neef, Mehmet K. Tur and Stefan Barth
Affiliation:
Keywords: RNA interference, specific knock-down, non-targeted delivery, targeted delivery, cell-specific ligands
Abstract: RNA interference (RNAi) is a powerful endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. The ability to block the expression of any disease-causing or disease-related protein emphasizes the huge therapeutic potential of this technology. In a clinical setting, however, the use of RNAi-based therapeutics is limited by their short serum half lives and poor uptake into cells. In this review, we provide an overview of recent patents in the field of short interfering RNA (siRNA) delivery and discuss recent progress in the development of efficient siRNA delivery vehicles enhancing the pharmacokinetic properties of RNAi-based therapeutics and promoting cellular uptake.
Export Options
About this article
Cite this article as:
Wullner Ulrich, Neef Inga, Tur K. Mehmet and Barth Stefan, Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002506
DOI https://dx.doi.org/10.2174/157489209787002506 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteomic Identification of a Monoclonal Antibody Recognizing Caveolin-1 in Hepatocellular Carcinoma with Metastatic Potential
Protein & Peptide Letters Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism HIV-1 IN Inhibitors: 2010 Update and Perspectives
Current Topics in Medicinal Chemistry ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry Unleashing the Potential of Microbial Natural Products in Drug Discovery: Focusing on <i>Streptomyces</i> as Antimicrobials Goldmine
Current Topics in Medicinal Chemistry Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery Natural Products as Anticancer Agents
Current Drug Targets Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Current Cancer Drug Targets Epothilone B and its Analogs - A New Family of Anticancer Agents
Mini-Reviews in Medicinal Chemistry Sculpted Amphiphilic Liposomal Particles for Modifiable Medicinal Applications
Current Drug Discovery Technologies Natures Lessons to Design an Effective, Rational and Selective Drug for Soft Tissue Sarcoma Treatment: The Ecteinascidins
Drug Design Reviews - Online (Discontinued) Virally Encoded Polymerases as Targets for Chemotherapy: Application to HIV and HBV
Current Medicinal Chemistry - Anti-Infective Agents Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine